Literature DB >> 34288798

Retinal Microvascular Alterations in Patients with Quiescent Posterior and Panuveitis Using Optical Coherence Tomography Angiography.

Aniruddha Agarwal1, Sushil Bhatt2, Shreya Keshari2, Roel J Erckens3, Tos T J M Berendschot3, C A B Webers3, Rupesh Agrawal2, Reema Bansal2, Vishali Gupta2.   

Abstract

PURPOSE: To quantify retinochoroidal vascular parameters using swept-source optical coherence tomography (SS-OCTA) in quiescent posterior and panuveitis.
METHODS: In this cross-sectional study, subjects with quiescent posterior and panuveitis underwent fundus imaging using SS-OCTA (DRI Triton®, Topcon, Japan). The metrics calculated were fractal dimension (FD), foveal avascular zone (FAZ) area, retinal vascularity index (capillary density index-CDI), and choroidal vascularity index (CVI).
RESULTS: We included 38 eyes of 20 patients, 9 males aged 34.7 ± 10.5 years, 30 eyes of 30 age- and gender-matched healthy controls, 10 females aged 33.6 ± 8.5 years. Comparing patients with controls, we found a lower FD (p < .001), larger FAZ (p > .001), lower CDI in the superficial plexus (p = .019), and lower CVI (p < .001). We also found lower retinal and choroidal and thicknesses (p < .001 and p = .025, respectively).
CONCLUSIONS: Patients with quiescent posterior and panuveitis have a significantly reduced retinochoroidal vascular density compared to healthy control subjects.

Entities:  

Keywords:  Optical coherence tomography angiography; choroidal vascularity index; fractal dimension; posterior uveitis; quiescent uveitis

Year:  2021        PMID: 34288798     DOI: 10.1080/09273948.2021.1954200

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  1 in total

1.  Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report.

Authors:  Eun Kyoung Lee; Baek-Lok Oh; Chang Ki Yoon; Un Chul Park
Journal:  BMC Ophthalmol       Date:  2022-06-03       Impact factor: 2.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.